Home › Scleroderma
Pag-aaral pangklinika para sa Scleroderma na nagre-recruit sa U.S.
33 pag-aaral para sa Scleroderma ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- New York City, NY11 pag-aaral
- Chicago, IL10 pag-aaral
- Ann Arbor, MI10 pag-aaral
- Houston, TX9 pag-aaral
- Los Angeles, CA7 pag-aaral
- Boston, MA7 pag-aaral
- Durham, NC7 pag-aaral
- Philadelphia, PA6 pag-aaral
- Baltimore, MD6 pag-aaral
- New Orleans, LA6 pag-aaral
- Pittsburgh, PA5 pag-aaral
- Dallas, TX5 pag-aaral
- Edison, NJ4 pag-aaral
- Charleston, SC4 pag-aaral
- Kansas City, KS4 pag-aaral
- Washington, DC4 pag-aaral
- Phoenix, AZ4 pag-aaral
- Plantation, FL4 pag-aaral
- Miami, FL4 pag-aaral
- New Haven, CT4 pag-aaral
- Mountain View, CA3 pag-aaral
- Cedar Rapids, IA3 pag-aaral
- Charlotte, NC3 pag-aaral
- Aurora, CO3 pag-aaral
- Jacksonville, FL3 pag-aaral
- Tucson, AZ3 pag-aaral
- St. Louis, MO3 pag-aaral
- San Diego, CA3 pag-aaral
- Minneapolis, MN3 pag-aaral
Ayos sa estado
- Alabama3 pag-aaral
- Arizona6 pag-aaral
- California13 pag-aaral
- Colorado4 pag-aaral
- Connecticut4 pag-aaral
- District of Columbia4 pag-aaral
- Florida9 pag-aaral
- Illinois11 pag-aaral
- Iowa3 pag-aaral
- Kansas5 pag-aaral
- Kentucky3 pag-aaral
- Louisiana6 pag-aaral
- Maryland6 pag-aaral
- Massachusetts7 pag-aaral
- Michigan10 pag-aaral
- Minnesota5 pag-aaral
- Missouri3 pag-aaral
- New Jersey5 pag-aaral
- New York11 pag-aaral
- North Carolina9 pag-aaral
- Ohio4 pag-aaral
- Pennsylvania10 pag-aaral
- South Carolina4 pag-aaral
- Tennessee5 pag-aaral
- Texas12 pag-aaral
- Virginia3 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06655155Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT03816345A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT07497087A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
Nagre-recruitPhase 1
Edad 18 hanggang 74 · Lahat ng kasarian · Na-update Set 10, 2026 · NCT07085104A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 8, 2026 · NCT05878717FT839 in Autoimmune Diseases
Nagre-recruitPhase 1/2
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Set 2, 2026 · NCT07800871A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
Nagre-recruitPhase 1
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Ago 28, 2026 · NCT06925542Platform Clinical Study for Conquering Scleroderma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 18, 2026 · NCT06195072RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
Nagre-recruitPhase 2/3
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT06328777Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
Nagre-recruitPhase 2
Edad 8 hanggang 60 · Lahat ng kasarian · Na-update Ago 14, 2026 · NCT03630211A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
Nagre-recruitPhase 1/2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Ago 7, 2026 · NCT06733935AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 31, 2026 · NCT06991114A Study of AZD0120 in Autoimmune Diseases
Nagre-recruitPhase 1
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Hul 28, 2026 · NCT07295847Diffuse Cutaneous Scleroderma (DSSc) SFDI Study
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 23, 2026 · NCT07090226A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 14, 2026 · NCT07115745A Study of Microbiome Transplantation for the Treatment of Constipation and/or Significant Bloating in Patients With Systemic Sclerosis
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 8, 2026 · NCT06827977Systemic Sclerosis DIet for GastrointESTinal Symptoms
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 1, 2026 · NCT07402226US Zamto-cel Autoimmune Diseases
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 11, 2026 · NCT06708845A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
Nagre-recruitPhase 1
Edad 12 hanggang 70 · Lahat ng kasarian · Na-update May 22, 2026 · NCT06308978Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Hanggang edad 90 · Lahat ng kasarian · Na-update May 12, 2026 · NCT01808937Intralesional Injection of STS in Treatment of Calcinosis
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update May 5, 2026 · NCT06672822Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 15, 2026 · NCT06434363A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 31, 2026 · NCT07047690Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Nagre-recruitPhase 2
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Mar 27, 2026 · NCT03844061Open Label Treprostinil Raynaud's Study
Nagre-recruitPhase 4
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 24, 2026 · NCT07112183Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.